Skip to main content
  • Investors
  • Mediaopen in a new window
  • Contact Usopen in a new window
  • |
Ironwood Logoopen in a new window
  • Company
  • Science & Medicine
  • Patients
  • Responsibility
  • Careers
  • IR Home
  • Why Invest
  • Events & Presentations
  • Corporate Governance
    • Governance Documents
    • Executive Management
    • Board of Directors
    • Committee Composition
    • Annual Meeting
    • Contact the Board
  • Financials
    • Quarterly Results
    • Annual Reports
    • SEC Filings
  • Press Releases
  • Investor Contacts
    • Investor Emails Alerts
    • RSS Feeds
  • Stock Information
    • Stock Quote & Chart
    • Historical Stock Quote
    • Analyst Coverage
    • Investor FAQs
  • IR Home
  • Why Invest
  • Events & Presentations
  • Corporate Governance
    • Governance Documents
    • Executive Management
    • Board of Directors
    • Committee Composition
    • Annual Meeting
    • Contact the Board
  • Financials
    • Quarterly Results
    • Annual Reports
    • SEC Filings
  • Press Releases
  • Investor Contacts
    • Investor Emails Alerts
    • RSS Feeds
  • Stock Information
    • Stock Quote & Chart
    • Historical Stock Quote
    • Analyst Coverage
    • Investor FAQs
Close
Close
  • Investors
  • Company
  • Product
  • Research & Development
  • Patients
  • Partnerships
  • Careers
Close

Press Releases

Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
August 8, 2023
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
July 25, 2023
Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call
June 29, 2023
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
June 16, 2023
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
June 12, 2023
Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old
May 22, 2023
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases
May 9, 2023
Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences Conference
May 8, 2023
Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023
May 4, 2023
Ironwood Pharmaceuticals Reports First Quarter 2023 Results; Maintains Full Year 2023 Financial Guidance
April 24, 2023
Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
April 20, 2023
Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call
February 27, 2023
Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences
February 16, 2023
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results
February 13, 2023
Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old
February 2, 2023
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Investor Update Call
January 9, 2023
Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance and Announces FY 2023 Financial Guidance
January 4, 2023
Ironwood Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

Investor Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Ironwood Pharmaceuticals, Inc., we strive to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Ironwood Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.

* Required

*
*





Email Alert Sign Up Confirmation

Ironwood Logoopen in a new window
  • Investors
  • Media
  • Contact us
Follow us on Linkedin Follow us on Twitter
  • COMPANY
  • Company Overview
  • Leadership
  • Open Payments & Transparecy
  • SCIENCE & MEDICINE
  • Therapeutic Focus
  • Pipeline
  • Product
  • PATIENTS
  • Overview
  • RESPONSIBILITY
  • Overview
  • Diversity, Equity & Inclusion
  • Sustainability
  • Safety & Compliance
  • Patients & Research
  • Community Giving
  • CAREERS
  • Working at Ironwood
  • Internships, Co-ops & Fellowships
  • Open Positions
  • Copyright © Ironwood. All rights reserved Powered By Q4 Inc. 5.77.0.2 (opens in new window)
  • Privacy Policy
  • California Privacy Policy
  • Site Map
  • Terms of Use